NCI-H1781 Cells

The NCI-H1781 cell line is a human non-small cell lung carcinoma (NSCLC) model derived from a lung adenocarcinoma. This cell line is particularly noteworthy for harboring the ERBB2 (HER2) G776insV_G/C mutation, an in-frame insertion in exon 20 that is functionally activating. Such mutations are known drivers in a subset of lung cancers and make NCI-H1781 a useful model for studying HER2-targeted therapies and resistance mechanisms. The ERBB2 mutation in NCI-H1781 contributes to constitutive kinase activation and downstream signaling via pathways such as PI3K/AKT and MAPK, thereby supporting cell proliferation and survival independently of external growth factors. In molecular profiling studies, NCI-H1781 demonstrates elevated levels of ERBB2 transcript and protein, consistent with its genetic alteration. Additionally, this cell line is often employed in pharmacogenomic investigations, as its sensitivity to HER2 inhibitors such as lapatinib or afatinib can vary depending on cellular context and combinatorial targeting strategies. It also exhibits resistance to EGFR inhibitors, which distinguishes it from EGFR-mutant lung cancer models and underscores the therapeutic relevance of HER2-specific targeting. Given its well-characterized genetic background and robust growth properties in vitro, NCI-H1781 serves as a reliable preclinical model for testing HER2-targeted compounds and exploring mechanisms of therapeutic resistance in lung adenocarcinoma.